Advertisement


R. Katie Kelley, MD, on Biliary Tract Cancer: Data From KEYNOTE-966 on Pembrolizumab, Gemcitabine, and Cisplatin

AACR Annual Meeting 2023

Advertisement

R. Katie Kelley, MD, of the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, discusses phase III findings of the KEYNOTE-966 study, which showed that adding the immune checkpoint inhibitor pembrolizumab to gemcitabine and cisplatin improved overall survival in patients with untreated metastatic or unresectable biliary tract cancer. (Abstract CT008)



Related Videos

Issues in Oncology

Carmen E. Guerra, MD, MSCE, on Strategies for Equitable Access to Cancer Clinical Trials

Carmen E. Guerra, MD, MSCE, of the University of Pennsylvania Abramson Cancer Center, discusses the ways in which community outreach, programs to help patients access cancer clinical trials, and institutional policies such as ASCO’s Just Ask program can help increase equity, diversity, and inclusion in cancer clinical trials and reduce unconscious bias.

Supportive Care
Symptom Management
Breast Cancer
Colorectal Cancer

Lindsay L. Peterson, MD, on Exercise and Cancer Outcomes

Lindsay L. Peterson, MD, of the Washington University, St. Louis, discusses the value of physical activity in improving cancer prognosis, especially for patients with breast or colon cancer. Aerobic exercises and resistance training are recommended during and after treatment. Exercise may help inhibit tumor growth, improve quality of life by decreasing fatigue and anxiety, build muscle mass, increase physical function, and reduce surgical complications and treatment delays.

Solid Tumors

Timothy A. Yap, MD, PhD, on New Findings on Treating Solid Tumors With PARP and ATR Inhibitors

Timothy A. Yap, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses safety and efficacy data on three different PARP inhibitors combined with the ATR inhibitor camonsertib in patients with solid tumors harboring DNA damage response alterations. The findings showed that low-dose intermittent regimens of camonsertib and different PARP inhibitor combinations were safe. In addition, anticancer activity was observed in patients with platinum- and PARP inhibitor–resistant tumors. Patients with late-line ovarian cancer derived the most benefit from therapy. (Abstract CT018)

Solid Tumors
Supportive Care

Christina M. Dieli-Conwright, PhD, MPH, on Resistance Exercise as Medicine: Improving Health and Cancer Outcomes

Christina M. Dieli-Conwright, PhD, MPH, of Dana-Farber Cancer Institute, discusses her research on the ways in which postdiagnosis exercise, particularly resistance exercise, can build strength and muscle mass and affect cancer outcomes. She also describes her focus on biomarkers related to body composition, inflammation, metabolic dysregulation, and cognition—all influenced by exercise.

Hepatobiliary Cancer

Pierce K.H. Chow, PhD, MBBS, on Hepatocellular Carcinoma: New Data From the IMbrave050 Trial of Atezolizumab, Bevacizumab, and Active Surveillance

Pierce K.H. Chow, PhD, MBBS, of the National Cancer Centre, Singapore and Duke-NUS Medical School, discusses phase III findings showing that, for patients with hepatocellular carcinoma at high risk of disease recurrence, adjuvant therapy with atezolizumab plus bevacizumab after resection or thermal ablation was more effective than active surveillance. According to Dr. Chow, these results could lead to reassessment of surgical resection in this disease. (Abstract CT003)

Advertisement

Advertisement



Advertisement